When will the nicotine vaccine be ready?;¿Cuánto falta para la vacuna antinicotina?

Archivos de Bronconeumologia

Volumn 41, Issue 1, 2005, Pages 2-4

  De Granda Orive, J I ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE VACCINE; UNCLASSIFIED DRUG; VACCINE; NICOTINE;

ADDICTION; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; EDITORIAL; HUMAN; LOCOMOTION; PHASE 1 CLINICAL TRIAL; PRIMARY PREVENTION; TREATMENT OUTCOME; VACCINE PRODUCTION; ANIMAL; IMMUNOLOGY; SMOKING;

ANIMALS; HUMANS; NICOTINE; SMOKING; VACCINES;

EID: 14344256310     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070277     Document Type: Editorial

References (30)

1. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Shuster CR. Changes in heroin self administration by rhesus monkey after morphine immunization. Nature. 1974;252:708-10.
2. Killian A, Bonese K, Rothberg RM, Wainer BH, Schuster CR. Effects of passive immunization against morphine on heroin administration. Pharmacol Biochem Behav. 1978;9:347-52.
3. Granda Drive JI, Solano Reina S, Jiménez Ruiz CA, Gutiérrez Jiménez T, Martínez Albiach JM. La vacuna antinicotina. Otoneumoalergia Práctica. 2003;12:20-4.
4. Granda Orive JI. El tabaquismo como enfermedad adictiva crónica. En: Jiménez Ruiz CA, Fagerström K, editores. Tratado de tabaquismo. Grupo Aula Médica. En prensa. 2004.
5. Carrera MRA, Ashley JA, Parsons LH, Wirsching P, Koob GF, Janda KD. Suppression of psychoactive effects of cocaine by active inmunization. Nature. 1995;378:727-30.
6. Fox BS, Kantak KM, Edwards MA, Black KM, Böllinger BK, Botka AJ, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Medicine. 1996;2:1129-32.
7. Keyler DA, Hieda Y, Peter JS, Pentel PR. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res. 1999;1:241-9.
8. Hieda Y, Keyler DE, Vandervoort JT, Kane JK, Ross CA, Raphael DE, et al. Active inmunization alters the plasma nicotine concentration in rats. J Pharmacol Experimental Ther. 1997;283:1076-81.
9. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Inmunopharmacol. 2000;22:809-19.
10. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behv. 2000;65:191-8.
11. Lindblom N, De Villiers SHL, Kalayanov G, Gordon S, Johansson AM, Svensson TH. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration. 2002;69:254-60.
12. De Villiers SHL, Lindhom N, Kalayanov G, Gordon S, Malmerfelt A, Johansson AM, et al. Active immunization against nicotine-induced dopamine release in the rats nucleus accumbens shell. Respiration. 2002;69;247-53.
13. Malin DH, Lake JR, Lin A, Saldana M, Balch L, Irvin ML, et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav. 2001;68:87-92.
14. TA-NIC nicotine vaccine. Disponible en: www.xenova.co.uk/dc_ta_nic.html
15. Clair Roberts JS, Dobson J, Wood D, Settles M. Safety and imnunogenicity of nicotine conjugate vaccine. Proceedings of Annual Meeting of the College on Problems of Drug Dependence CPDD; 2002, June; Québec City.
16. Clair Roberts JS, Akers CVR, Vanhinsbergh L, McKenna KA, Wood DM, Jack L, et al. Longitudinal safety and inmunogenicity data of TA-NIC, a novel nicotine vaccine. Proceedings of Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT); 2003, November; Padua.
17. Lindmayer K, Horwith G, Fattom A, Naso R, Fuller S, Muenz L, et al. Results of a phase 1, double blinded, controlled safety and inmunogenicity trial of NICVAX™, a conjugated nicotine vaccine. Proceedings of IV European Conference of the Society for Research on Nicotine and Tobacco (SRNT); 2002, October; Santander.
18. Lindmayer K, Horwith G, Fattom A, Naso R, Fuller S, Muenz L, et al. Results of a phase 1, double blinded, controlled safety and inmunogenicity trial of NICVAX™, a conjugated nicotine vaccine. Proceedings of IV European Conference of the Society for Research on Nicotine and Tobacco (SRNT); 2003, November; Padua.
19. Bunce CJ, Loudon PT, Akers C, Dobson J, Wood DM. Development of vaccines to help treat drug dependence. Curr Opin Mol Ther. 2003;5:58-63.
20. Satoskar SD, Keyler DE, Le Sage MG, Raphael DE, Ross C, Pentel PR. Tissue dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol. 2003;3:957-70.
21. Pentel P, Malin D. A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration. 2002;69:193-7.
22. Cerny EH, Lévy R, Mauel J, Mpandi M, Mutter M, Henzelin-Nkubana C, et al. Preclinical development of a vaccine against smoking. Onkologie. 2002;25:406-11.
23. Sanderson SD, Cheruku SR, Padmanilayam MP, Vennerstrom JL, Thiele GM, Palmatier MI, et al. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol. 2003;3:137-46.
24. Carrera MRA, Ashley JA, Hoffman TZ, Isomura S, Wirsching P, Koob GF, et al. Investigation using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem. 2004;12:563-70.
25. Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther. 2000;68:35-43.
26. Meijler MM, Matsushita M, Altobell LJ, Wirsching P, Janda KD. A new strategy for improved nicotine vaccines using conformationally constrained haptens. J Am Chem Soc. 2003;125:7164-5.
27. Respiratory Reviews.com. New approaches to smoking cessation show promise. Disponible en: http://www.respiratoryreviews.com /mar01/rr_cessation. html
28. Hall W. The prospects for immunotherapy in smoking cessation. Lancet. 2002;360:1089-91.
29. Vocci FJ, Chiang CN. Vaccines against nicotine: how effective are they likely to be in preventing smoking? CNS Drugs. 2001;15: 505-14.
30. Keyler DE, Shoeman D, Lessge MG, Calvin AD, Pentel PR. Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J Pharmacol Exp Ther. 2003;305:587-92.